The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2017 | The history of collaboration in acute promyelocytic leukemia (APL) research
Francesco Lo-Coco, MD, from the University Tor Vergata, Rome, Italy, discusses the history of collaboration in acute promyelocytic leukemia (APL, APML) research at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany. He describes how this is more of a tradition in Europe, starting with the French pioneer Jean Bernhard in the 1970s, who recognized that patients with this leukemia subtype responded to the drug daunorubicin. Trials with anthracyclines alone were started in Europe, but not immediately followed in the US. However, US investigators pioneered the combination of anthracyclines with all-trans retinoic acid. Prof. Lo Coco concludes that the whole process has been collaborative.
